News Article

Pharmatech's TrialPlus+ Changes Clinical Trials Industry
Date: Sep 18, 2013
Source: ( click here to go to the source)

Featured firm in this article: Pharmatech Oncology Inc of Denver, CO



Pharmatech Inc. introduced their communications and trial management technology platform: TrialPlus+, on August 1st, which was developed for research sites and physicians to be able to access a broad range of clinical trials that are available for their centers.

"It's one of the most powerful communication platforms ever developed for the clinical trial community and it can instantaneously communicate with our 2,200 investigators and research staff," Rob Bohacs, CEO of Pharmatech, explained.

TrialPlus+ streamlines communication; so when a research site needs information, regarding a clinical trial, they need only log on to TrialPlus+ to access available clinical studies, supporting documentation, and value-added benefits of each study. Each TrialPlus+ site is also specialized for each user including: organizing documents, finding new trials and allowing easy access to critical information for each study.

Before, there was a great deal of time spent calling back and forth, between the sites and project managers, and researching information online. TrialPlus+ cuts down on the time spent doing these activities without eliminating the quality or quantity of communication.

Available for iPhone and Android, as well as the majority of the browsers, TrialPlus+ not only significantly improves enrollment, reaches a diverse set of staff on a daily basis but also increases the transparency of the industry.

About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.